Table 1.
Clinicopathological variables.
| Variable | Number (%) | |
|---|---|---|
| All cases | 92 | |
| Gender | Male | 55 (60) |
| Female | 37 (40) | |
| Data pertaining to pCRC | ||
| TNM classification | T1-2 | 6 (7) |
| T3 | 71 (77) | |
| T4 | 15 (16) | |
| N0 | 40 (43) | |
| N1 | 28 (30) | |
| N2 | 24 (26) | |
| M1 | 36 (39) | |
| pCRC location | Right colon | 24 (26) |
| Left colon + rectum | 68 (74) | |
| Data pertaining CLM | ||
| Age | Median (IQR) | 68 (61–73) |
| Performance status | ECOG 0 | 66 (72) |
| ECOG 1 and 2 | 22 (24) | |
| NA | 4 (4) | |
| Clinical risk score | 0-2 | 68 (74) |
| 3-4 | 23 (25) | |
| NA | 1 (1) | |
| Microsatellite instability | 1 (1) | |
| NACT | No NACT | 47 (51) |
| NACT | 45 (49) | |
| Resection interval (weeks), median (range) | 8 (3–38) | |
| Number of NACT cycles, median (range) | 4 (3–12) | |
| NACT regimens | Fluoropyrimidine + oxaliplatin | 31 (69) |
| Fluoropyrimidine + irinotecan | 6 (13) | |
| Fluoropyrimidine + other | 7 (16) | |
| Oxaliplatin monotherapy | 1 (2) | |
| RECIST response (n = 44) | Partial response | 19 (43) |
| Stable disease | 19 (43) | |
| Progressive disease | 6 (14) | |
pCRC, primary colorectal cancer; TNM, Union for International Cancer Control TNM classification 7th edition; CLM, colorectal liver metastases; ECOG, Eastern Cooperative Oncology Group; NACT, neoadjuvant chemotherapy; RECIST version 1.1, The Response Evaluation Criteria in Solid Tumors.